Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 8 of 8 citing Wong: Some ethical considerations for the “off-label” use of drugs such as Avastin. (0.06 sec) 

Intravitreal ranibizumab and bevacizumab: a review of risk


RM Dafer, M Schneck, TR Friberg, WM Jay - Seminars in Ophthalmology, 2007 - informahealthcare.com
Ranibizumab (Lucentis®), a recombinant monoclonal antibody, blocks all active
forms of vascular endothelial growth factor A and was the first treatment for
age-related macular degeneration shown to improve visual acuity in a ...
Cited by 24 - Related articles - BL Direct - All 6 versions

Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration

- prsjournal.com
RM Klein, RB Klein - Retina, 2007 - journals.lww.com
There is controversy over the use of ranibizumab (Lucentis; Genentech, Inc.,
South San Francisco, CA) and bevacizumab (Avastin; Genentech, Inc.) for treating
wet age-related macular degeneration (AMD), the leading cause of blindness ...
Cited by 7 - Related articles - BL Direct - All 3 versions

Off-label use of medicines: Medical research and medical practice


B Khamar - Indian Journal of Ophthalmology, 2007 - pubmedcentral.nih.gov
Off-label (unlabelled or unapproved) use of an approved product refers to the
use of an approved product in a scenario that is not included or is disclaimed
in the product information. Examples include use for a different ...
Cited by 2 - Related articles - BL Direct - All 4 versions

[CITATION] Intravitreal injection: balancing the risks


NV Chong, T Adewoyin - Eye, 2007 - nature.com
Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit manuscript; Register; Subscribe; RCOphth ...
Cited by 2 - Related articles - BL Direct - All 4 versions

Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: …

- prsjournal.com
F Ziemssen, S Grisanti, KU Bartz-Schmidt, MS … - Drugs &# 38; Aging, 2009 - ingentaconnect.com
Abstract. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . 295 1. Approved Indications of Bevacizumab. . . . . . . . . . . . ...
Cited by 1 - Related articles - All 7 versions

Avastin in myopic choroidal neovascularisation: is age the limit?

- prsjournal.com
D Wong, KKW Li - British Journal of Ophthalmology, 2008 - bjo.bmj.com
There are a growing number of publications supporting the use of Avastin
(bevacizumab) for choroidal neovascularisation (CNV) secondary to pathological
myopia (table 1).1 – 8 In this issue, Arias et al (see page 1035) ...
Cited by 1 - Related articles - All 4 versions

The ethics of off-label use of drugs: oncology pharmacy in Italy


AB PharmD, RP MD - Journal of Clinical Pharmacy and Therapeutics - interscience.wiley.com
The off-label use of drugs is very common in cancer treatment for many reasons.
This practice is challenging for pharmacists who practice in oncology, for
bureaucratic and medico-legal reasons and for reasons concerning ethics. ...
Related articles

[PDF] BRATS


IDAAPO TRATAMENTO, MRÀI DA … - bvsms.saude.gov.br
A degeneração macular relacionada à idade (DMRI) é uma doença ocular
caracterizada pelo dano à mácula. Quando há lesão na mácula, a região
central das imagens é bloqueada, ocorrendo perda progressiva da visão ...
Related articles - View as HTML - All 10 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google